GlassScriptPhysician profile
Julia L Clift
NPI 1649874736
$4,614.30
in general payments reported to CMS, 2019-2025
20 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,913 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,554 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,554.31 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.43 | 2024-2025 | |
| Ucb, INC. | $765.20 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $644.34 | 2024-2025 | Otezla, Enbrel, Enbrel |
| Glaxosmithkline, LLC. | $300.70 | 2024-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $249.54 | 2024-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $247.06 | 2024-2025 | |
| Pfizer INC. | $211.60 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $197.04 | 2024-2025 | Orencia |
| Organon LLC | $193.63 | 2024-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $171.75 | 2024-2025 | Acthar |
| Lilly USA, LLC | $166.71 | 2024-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.27 | 2024-2025 | Ofev |
| Fresenius Kabi USA, LLC | $95.48 | 2024-2025 | Idacio, Tyenne |
| Radius Health, INC. | $59.22 | 2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $51.16 | 2025 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $46.22 | 2024 | |
| Genentech USA, INC. | $37.40 | 2024-2025 | Actemra |
| Genzyme Corporation | $31.01 | 2025 | |
| Lundbeck LLC | $14.81 | 2024 | Vyepti |
| Janssen Biotech, INC. | $13.73 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Clift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.